In a recent LCGC peer exchange on the topic of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), Judith Hey-Hadavi , vice president of Medical Affairs at Worldwide Clinical Trials, and Nicole Snow Pharm D, BCSCP, CSP , clinical pharmacist at Olympia Pharmaceuticals, explored the evolving landscape of GLP-1 therapies
The pharmaceutical role of glycine Every injectable peptide faces a stability challenge
Thigh: May result in slightly slower absorption for some, which might move the peak closer to the 72-hour mark
LegitScript evaluates pharmacies against strict criteria covering legal compliance, operational transparency, and patient safety
More recently, in the OASIS 1 trial, participants using a 50 mg dose of oral semaglutide saw an impressive 15.1% average weight loss over 68 weeks, with 85% losing at least 5% of their body weight, and 34% losing 20% or more